Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has benefited from meaningful positive changes in fundamentals: the consensus estimate for December, 2024 increased significantly, the consensus estimate for December, 2023 increased significantly, and significant quarterly earnings acceleration occurred.
Recent notable positive changes in investment behavior have benefitted Amphastar Pharmaceuticals Inc (NASDAQ: AMPH): its shorter term price trend turned up.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, AMPH is expected to continue to be a major Value Builder.
Amphastar Pharmaceuticals has a current Value Trend Rating of B (Positive). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Amphastar Pharmaceuticals has a slightly negative Appreciation Score of 34 but a very high Power Rating of 93, with the Positive Value Trend Rating the result.
Recent Price Action
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) stock closed at $56.59 on 11/20/23 after an increase of 1.3%. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 7.7% during the last week.